Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease

European Journal of Neurology

Volumn 18, Issue 12, 2011, Pages 1373-1378

  Stocchi, F ^a   Rabey, J M ^b  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Entacapone; Motor control; Parkinson's disease; Rasagiline

Indexed keywords

ENTACAPONE; LEVODOPA; PLACEBO; RASAGILINE;

ADD ON THERAPY; ADULT; ARTICLE; BRADYKINESIA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FACIAL EXPRESSION; FEMALE; GAIT DISORDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE RIGIDITY; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPEECH DISORDER; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE;

AGED; ANTIPARKINSON AGENTS; CATECHOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DYSARTHRIA; FACIAL EXPRESSION; FEMALE; HUMANS; HYPOKINESIA; INDANS; LEVODOPA; MALE; MIDDLE AGED; MONOAMINE OXIDASE INHIBITORS; MOTOR ACTIVITY; MUSCLE RIGIDITY; NITRILES; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; TREMOR;

EID: 81855207343     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2011.03512.x     Document Type: Article

References (20)

1. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001; 16: 448-458.
2. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. J Am Med Assoc 2000; 284: 1931-1938.
3. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351: 2498-2508.
4. Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord 2005; 20: 224-230.
5. Rahman S, Griffin HJ, Quinn NP, Jahanshahi M. Quality of life in Parkinson's disease: the relative importance of the symptoms. Mov Disord 2008; 23: 1428-1434.
6. Koller WC, Tse W. Unmet medical needs in Parkinson's disease. Neurology 2004; 62: S1-S8.
7. Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. Eur J Neurol 2006; 13: 1186-1202.
8. Pahwa R, Factor SA, Lyons KE, et al. Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66: 983-995.
9. Youdim MB, Gross A, Finberg JP. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 2001; 132: 500-506.
10. Youdim MB, Riederer PF. A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease. Neurology 2004; 63: S32-S35.
11. Thebault JJ, Guillaume M, Levy R. Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor. Pharmacotherapy 2004; 24: 1295-1305.
12. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005; 365: 947-954.
13. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005; 62: 241-248.
14. Rabey JM, Sagi I, Huberman M, et al. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol 2000; 23: 324-330.
15. Langston JW, Widner H, Goetz CG, et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 1992; 7: 2-13.
16. Levy G, Louis ED, Cote L, et al. Contribution of aging to the severity of different motor signs in Parkinson disease. Arch Neurol 2005; 62: 467-472.
17. Gordin A. The efficacy and safety of COMT inhibition in clinical trials in Parkinson's disease. Mov Disord 1996; 11: 267.
18. Rabey M, Fitzer-Attas C. Effect of adjunct rasagiline on dopaminergic and non-dopaminergic motor features of Parkinson's disease. Mov Disord 2007; 22: S92.
19. Hely MA, Morris JG, Traficante R, Reid WG, O'Sullivan DJ, Williamson PM. The sydney multicentre study of Parkinson's disease: progression and mortality at 10years. J Neurol Neurosurg Psychiatry 1999; 67: 300-307.
20. Shulman L, Gruber-Baldini A, Anderson K, Fishman PS, Reich S, Weiner W. Longitudinal assessment of a clinically meaningful difference in the UPDRS. Neurology 2009; 72: A414.